“…Although liver transplantation, surgery, and interventional radiology, Sorafenib (or Nexavar) as a receptor tyrosine kinase inhibitor has been applied to over half of the patients with HCC for years, recent 1 year relative survival rate is less than 50% (Fukuda et al, 2014;Graf et al, 2014). Because the side effects of Sorafenib are known severe with erythema multifomre, hand-foot syndrome (Yang et al, 2008), diarrhea, and vomiting and nausea (Berk et al, 2013), recently, herbal drugs (Hu et al, 2013) or natural compounds (Huynh et al, 2014) are attractive for the prevention or treatment for HCC alone or by combination therapy with Sorafenib (Cao et al, 2011;Hu et al, 2013;Huynh et al, 2014;Li et al, 2014a).…”